STOK
Stoke Therapeutics, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive. |
Common Stock
|
500 |
| 2026-07-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
6,728 |
| 2026-06-16 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. |
Common Stock
|
1,457 |
| 2026-06-03 | Smith Julie |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Burstein Jennifer |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Kaye Edward M. MD |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Krainer Adrian R. |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | Harrison Seth Loring |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | TZIANABOS ARTHUR |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-03 | LEVIN ARTHUR A |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Director Stock Option (Right to Buy)
|
17,786 |
| 2026-06-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,795 |
| 2026-05-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
2,243 |
| 2026-04-03 | Kahn Clare |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option award shall vest as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April, with the first tranche vesting on July 1, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |
Stock Option (Right to Buy)
|
30,782 |
| 2026-04-03 | Kahn Clare |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-04-01 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,838 |
| 2026-03-20 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
Common Stock
|
8,692 |
| 2026-03-20 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.12 per share, inclusive. |
Common Stock
|
601 |
| 2026-03-19 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,461 |
| 2026-03-19 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. |
Common Stock
|
1,365 |
| 2026-03-19 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. The option is fully vested and exercisable. |
Stock Option (Right to Buy)
|
1,365 |
| 2026-03-18 | Hoitt Jason |
Chief Patient Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. |
Common Stock
|
1,762 |
| 2026-03-18 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. |
Common Stock
|
103 |
| 2026-03-18 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. |
Common Stock
|
4,222 |
| 2026-03-18 | Leggett Thomas |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. |
Common Stock
|
37 |
| 2026-03-18 | Hoitt Jason |
Chief Patient Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. |
Common Stock
|
139 |
| 2026-03-18 | Leggett Thomas |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. |
Common Stock
|
2,173 |
| 2026-03-18 | Leggett Thomas |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. |
Common Stock
|
172 |
| 2026-03-18 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. |
Common Stock
|
6,100 |
| 2026-03-18 | Hoitt Jason |
Chief Patient Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. |
Common Stock
|
30 |
| 2026-03-18 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. |
Common Stock
|
483 |
| 2026-03-18 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. |
Common Stock
|
334 |
| 2026-03-18 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. |
Common Stock
|
72 |
| 2026-03-17 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. |
Common Stock
|
1,791 |
| 2026-03-17 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. |
Common Stock
|
2,587 |
| 2026-03-17 | Hoitt Jason |
Chief Patient Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. |
Common Stock
|
748 |
| 2026-03-17 | Leggett Thomas |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. |
Common Stock
|
922 |
| 2026-03-17 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. |
Common Stock
|
3,577 |
| 2026-03-17 | Hoitt Jason |
Chief Patient Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. |
Common Stock
|
1,033 |
| 2026-03-17 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. |
Common Stock
|
2,476 |
| 2026-03-17 | Leggett Thomas |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. |
Common Stock
|
1,274 |
| 2026-03-15 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Convert↑
Filing footnotes — Common Stock (Direct)
The reported total includes an aggregate 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). |
Common Stock
|
7,475 |
| 2026-03-15 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. |
Restricted Stock Units
|
7,475 |
| 2026-03-15 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
10,750 |
| 2026-03-15 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date. |
Restricted Stock Units
|
6,000 |
| 2026-03-15 | Kaye Edward M. MD |
Director |
Convert↑
|
Common Stock
|
35,500 |
| 2026-03-15 | Leggett Thomas |
Chief Financial Officer |
Convert↑
|
Common Stock
|
14,750 |
| 2026-03-15 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
13,100 |
| 2026-03-15 | Allan Jonathan |
GENERAL COUNSEL & CORP SEC |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |
Restricted Stock Units
|
12,000 |
| 2026-03-15 | Ticho Barry |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
10,000 |
| 2026-03-15 | Kaye Edward M. MD |
Director |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. |
Restricted Stock Units
|
35,500 |